PDGFR/CSF1R/KIT (multi-kinase)

Class

Inhaled multi-kinase inhibitor

PDGFR (platelet-derived growth factor receptor), CSF1R (colony-stimulating factor 1 receptor), and KIT are receptor tyrosine kinases that, when activated by their respective growth factors, drive proliferation and survival signals in specific cell types: PDGFR in fibroblasts and vascular smooth muscle cells, CSF1R in macrophages, and KIT in mast cells and some stromal cells. In diseases marked by excessive tissue remodeling—such as pulmonary vascular disease, where smooth muscle and fibroblast overgrowth thickens blood vessel walls, and fibrotic lung conditions—these three pathways can act in parallel to sustain abnormal cell growth, chronic inflammation, and scarring. A single small molecule that inhibits all three kinases can interrupt multiple reinforcing drivers of remodeling rather than just one, which may be more effective than a selective inhibitor when the disease process is multifactorial. Delivering such an inhibitor by inhalation, directly to the lung, is intended to concentrate drug exposure at the site of disease while limiting the amount reaching the rest of the body, since systemic inhibition of these kinases can affect normal tissue maintenance, immune cell function, and blood cell production. This mechanism is broadly relevant to pulmonary vascular and fibrotic diseases where growth factor–driven remodeling of lung architecture is a central feature.